Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onCARlytics + anti-CD19 ARTEMIS T-cell therapy
- Development stage
- Preclinical
- Lead developer
- Imugene
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
onCARlytics + anti-CD19 ARTEMIS T-cell therapy is a combination immunotherapy developed by Imugene and Eureka Therapeutics for the treatment of solid tumors. This therapy employs a 'mark and kill' strategy where Imugene's oncolytic virus, onCARlytics, infects tumor cells and forces them to express the B-lymphocyte antigen CD19. Subsequently, Eureka's anti-CD19 ARTEMIS T-cell therapy targets and eliminates these CD19-expressing tumor cells. The oncolytic virus primes the tumor microenvironment, making it more susceptible to T-cell therapy. The combination is administered intravenously.
02
Targets
Beyond the preview
Go deeper on onCARlytics + anti-CD19 ARTEMIS T-cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onCARlytics + anti-CD19 ARTEMIS T-cell therapy.